reports
- Jan Frederik Slijkerman
3Q25 results: Telenet, VodafoneZiggo, Virgin Media O2/Better than fear...
VodafoneZiggo, Telenet and Virgin Media O2 presented mixed results over 3Q25. Fortunately, KPIs are improving somewhat. Given the competitive end markets, our conviction to buy or sell the notes of any of the three companies remains low. Leverage remained stable QoQ. Nevertheless, we still see upside to the VMED and ZIGGO notes if either Vodafone or Telefonica were to acquire full ownership of their joint ventures or if the businesses where to IPO.
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Felix Fischer
- Hybridan Team
Hybridan Small Cap Feast: 22 October 2025
22nd October 2025 @HybridanLLP * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the day Admissions: None Delistings: None What’s baking in the oven? Potential** Initial ...
- Baptiste Salaville
- Bruno Cavalier
- Roy Külter
- Steven Boumans
ORA ORANGE SA
EO FAURECIA SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EN BOUYGUES SA
TNG TRANSGENE SA
SCR SCOR SE
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
VIRP VIRBAC SA
KER KERING SA
TPE PVA TEPLA AG
ISP INTESA SANPAOLO S.P.A.
01913 PRADA S.P.A.
AIXA AIXTRON SE
DLG DE'LONGHI S.P.A.
UCG UNICREDIT S.P.A.
MONC MONCLER SPA
VIG VIENNA INSURANCE GROUP AG WIENER VERSICHERUNG GRUPPE
VGP VGP NV
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
COFA COFACE SA
ALM ALMIRALL SA
ZGN ERMENEGILDO ZEGNA NV
ARYN ARYZTA AG
- Baptiste Salaville
- Bruno Cavalier
- Roy Külter
- Steven Boumans
ORA ORANGE SA
EO FAURECIA SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EN BOUYGUES SA
TNG TRANSGENE SA
SCR SCOR SE
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
VIRP VIRBAC SA
KER KERING SA
TPE PVA TEPLA AG
ISP INTESA SANPAOLO S.P.A.
01913 PRADA S.P.A.
AIXA AIXTRON SE
DLG DE'LONGHI S.P.A.
UCG UNICREDIT S.P.A.
MONC MONCLER SPA
VIG VIENNA INSURANCE GROUP AG WIENER VERSICHERUNG GRUPPE
VGP VGP NV
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
COFA COFACE SA
ALM ALMIRALL SA
ZGN ERMENEGILDO ZEGNA NV
ARYN ARYZTA AG
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive ...
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy Strasbourg, France, and Lund, Sweden, October 20, 2025, 08:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment...
Le virus oncolytique armé BT-001, développé par Transgene et BioInvent...
Le virus oncolytique armé BT-001, développé par Transgene et BioInvent, montre une activité antitumorale locale, à distance et durable chez des patients atteints de tumeurs avancées en échec thérapeutique BT-001, administré en combinaison avec pembrolizumab, est bien toléré et présente une activité antitumorale persistante dans des lésions injectées et non-injectées Les résultats obtenus soutiennent la poursuite du développement de BT-001 dans les tumeurs solides afin d'améliorer la réponse aux immunothérapies Strasbourg, France, et Lund, Suède, le 20 octobre 2025, 8 h 30 CEST – Transge...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
Transgene and BioInvent to Present Translational Data and Updated Clin...
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025 Poster presentation on BT-001 in combination with pembrolizumab has shown tumor shrinkage in both injected and non-injected lesions Strasbourg, France, and Lund, Sweden, October 13, 2025, 8:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and developmen...
Transgene et BioInvent présentent des données translationnelles et la...
Transgene et BioInvent présentent des données translationnelles et la mise à jour des résultats cliniques du virus oncolytique armé BT-001 à l’ESMO 2025 La présentation d’un poster de BT-001 en combinaison avec pembrolizumab montre une réduction tumorale dans des lésions injectées et non injectées Strasbourg, France, et Lund, Suède, le 13 octobre 2025, 8 h 30 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, et BioInvent International AB (« BioInvent ») (Nasdaq Stockholm : BINV), s...
Transgene to Present New Immunological Data from Phase I Trial of Indi...
Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025 Strasbourg, France, October 3, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting in-depth analysis of the neoantigen-specific T cell response from the randomized Phase I trial of its individualized therapeutic cancer vaccine, TG4050, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). SITC will tak...
Transgene présente de nouvelles données d’immunologie de la Phase I de...
Transgene présente de nouvelles données d’immunologie de la Phase I de TG4050, son vaccin thérapeutique individualisé, au SITC 2025 Strasbourg, France, le 3 octobre 2025, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, présente un poster, à la 40e conférence annuelle de la Société pour l’immunothérapie du cancer (SITC) mettant en avant l’analyse approfondie de la réponse cellulaire T spécifique des néoantigènes issue de l’essai randomisé de Phase I de son vaccin thérapeutiqu...
- Maxime Kogge
- Thomas Zlowodzki
BEKB BEKAERT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
FLY SOCIETE FONCIERE LYONNAISE SA
POM PLASTIC OMNIUM SE
SZG SALZGITTER AG
KOF KAUFMAN & BROAD SA
VOE VOESTALPINE AG
ACX ACERINOX SA
TRI TRIGANO SA
ERA ERAMET SA
NDA AURUBIS AG
SESL SES-IMAGOTAG SA
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
BRAV BRAVIDA HOLDING AB
TRE TECNICAS REUNIDAS SA
RIO RIO TINTO PLC
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
VUL VULCAN ENERGY RESOURCES
ATO ATOS SE
AAL ANGLO AMERICAN PLC
- Maxime Kogge
- Thomas Zlowodzki
BEKB BEKAERT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
FLY SOCIETE FONCIERE LYONNAISE SA
POM PLASTIC OMNIUM SE
SZG SALZGITTER AG
KOF KAUFMAN & BROAD SA
VOE VOESTALPINE AG
ACX ACERINOX SA
TRI TRIGANO SA
ERA ERAMET SA
NDA AURUBIS AG
SESL SES-IMAGOTAG SA
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
BRAV BRAVIDA HOLDING AB
TRE TECNICAS REUNIDAS SA
RIO RIO TINTO PLC
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
VUL VULCAN ENERGY RESOURCES
ATO ATOS SE
AAL ANGLO AMERICAN PLC
- Christophe Chaput
- Ahmed Ben Salem
VAC PIERRE & VACANCES SA
BVB BORUSSIA DORTMUND GMBH & CO. KGAA
BON BONDUELLE SCA
NANO NANOBIOTIX SA
CFEB COMPAGNIE D'ENTREPRISES CFE SA
SIGHT GENSIGHT BIOLOGICS SA
VIG VIENNA INSURANCE GROUP AG WIENER VERSICHERUNG GRUPPE
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
DGM DIAGNOSTIC MEDICAL SYSTEMS
SPIE SPIE SA
HOME NEINOR HOMES SA
WAGA WAGA ENERGY SA
CTPNV CTP NV
LHYFE LHYFE S.A.
ORP ORPEA
4X0 STEYR MOTORS AG
HAVAS HAVAS N.V
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.